Furthermore, splice variants in V600E BRAF-mutant-positive malignant melanoma patients were shown to be associated with vemurafenib resistance, indicating that aberrant splicing could be a novel mechanism of acquired resistance [48]. The gene discussed is BRAF; the disease is melanoma.